Future studies involving the selective targeting of hypomorphic p53 mutants to either hepatocytes or cholangiocytes will not only be important for determining how cell-autonomous and/or paracrine mechanisms related to p53 signaling drive hepatic dysfunction, but should also help to establish which arms of the p53 network are important for effecting arrest, senescence or death in each cell type, information that will undoubtedly be useful for furthering our understanding of the pathogenic underpinnings of liver disease. Here, TP53 is linked to liver disorder.